The primary scientific trial evaluating semaglutide and tirzepatide, two common, injectable weight-loss medication, has been revealed, inspecting their means to cut back weight and waist circumference. And one clearly comes out on prime.
Injectable GLP-1 receptor agonist medication Wegovy (semaglutide) and Zepbound (tirzepatide) have revolutionized weight reduction. However, unusually, nobody has in contrast the 2 to find out which one is healthier at shedding the kilos. Till now.
A brand new examine led by Weill Cornell Medicine in New York was the primary to undertake a head-to-head comparability of the load loss effectiveness of semaglutide and tirzepatide, and one among them clearly got here out on prime.
“Our examine reveals that remedy with tirzepatide was superior to semaglutide with respect to discount in physique weight and waist circumference,” mentioned lead and corresponding writer Louis Aronne, MD, a specialist in weight problems medication from Weill Cornell’s Comprehensive Weight Control Center.
Whereas each medication are GLP-1 receptor agonists, which implies they mimic the hormone glucagon-like peptide-1 that regulates urge for food and meals consumption, tirzepatide additionally acts on glucose-dependent insulinotropic polypeptide (GIP) receptors. In addition to regulating the discharge of insulin in response to meals, GIP receptors play a job in decreasing urge for food and enhancing emotions of fullness.
The part 3b clinical trial recruited 751 adults with weight problems however with out sort 2 diabetes. Contributors had been randomly assigned to obtain both the utmost tolerated dose of tirzepatide (10 mg or 15 mg) or the utmost tolerated dose of semaglutide (1.7 mg or 2.4 mg), delivered by under-the-skin or subcutaneous injection as soon as every week for 72 weeks. Contributors had been included if that they had a body mass index (BMI) of 30 kg/m2 or extra (that’s, overweight), or a BMI of 27 kg/m2 or extra (obese) plus a minimum of one weight-related complication, equivalent to hypertension, excessive levels of cholesterol, obstructive sleep apnea, or coronary heart illness. The examine’s main endpoint was the proportion change in weight from baseline to week 72. A secondary endpoint was a change in waist circumference over that point.
Contributors taking tirzepatide skilled a imply weight discount of 20.2% at 72 weeks, whereas these taking semaglutide diminished their weight by a imply of 13.7%. That signifies that weight reduction attributable to tirzepatide was 47% greater than that attributable to semaglutide. The imply lower in waist circumference for these on tirzepatide was 18.4 cm/7.2 in, and for these on semaglutide it was 13 cm/5.1 in – 42% greater for tirzepatide.
“Tirzepatide, whereas a single molecule, pharmacologically prompts two metabolic receptors, GIP and GLP-1, which have each overlapping and non-overlapping expression and performance,” Aronne mentioned. “This twin agonism of tirzepatide might contribute to the upper weight discount noticed within the present examine in comparison with semaglutide, a mono-agonist.”
The commonest hostile occasions for each remedy teams had been gastrointestinal, largely delicate to average in severity. They generally occurred because the remedy dose was being elevated.
The examine had strengths, too. Significantly the examine’s variety, which included individuals who recognized as Black/African American (19%) and Hispanic/Latino (26%), two populations which might be extra affected by weight problems in contrast with different racial and ethnic teams. Nevertheless, it additionally had limitations. Essentially the most important being that it was not a blinded examine, that means that individuals knew the drug they had been taking and its dose. Nevertheless, the researchers mentioned that their findings had been in line with these of earlier blinded research, rising their generalizability.
“Our examine reveals that remedy with tirzepatide was superior to semaglutide with respect to discount in physique weight and waist circumference,” mentioned Aronne.
The examine, funded by Eli Lilly, was offered at this 12 months’s European Congress on Obesity (ECO) in Malaga, Spain, and revealed in The New England Journal of Medicine.
Supply: European Association for the Study of Obesity (EASO)
